Compare SLQT & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLQT | EYPT |
|---|---|---|
| Founded | 1999 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.3M | 419.9M |
| IPO Year | 2020 | 2005 |
| Metric | SLQT | EYPT |
|---|---|---|
| Price | $0.44 | $4.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $2.88 | ★ $31.80 |
| AVG Volume (30 Days) | 1.3M | ★ 3.6M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,618,499,000.00 | $7,539,000.00 |
| Revenue This Year | $10.97 | N/A |
| Revenue Next Year | $6.14 | $3,115.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.02 | N/A |
| 52 Week Low | $0.46 | $3.42 |
| 52 Week High | $2.22 | $19.11 |
| Indicator | SLQT | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 29.49 | 34.65 |
| Support Level | N/A | $3.95 |
| Resistance Level | $0.78 | $14.72 |
| Average True Range (ATR) | 0.03 | 0.32 |
| MACD | 0.00 | 0.26 |
| Stochastic Oscillator | 6.20 | 47.67 |
SelectQuote Inc is a technology-enabled, direct-to-consumer (DTC) distribution and engagement platform for selling insurance policies and healthcare services. Its insurance distribution business allows consumers to transparently and conveniently shop for senior health, life, and automobile and home insurance policies from a curated panel of the nation's insurance carriers. It operates in three reportable segments: Senior, Healthcare Services, and Life. Senior sells senior Medicare-related health insurance products. Healthcare Services includes SelectRx, Healthcare Select, and SPM. Healthcare Services provides products and services to its Medicare policyholders, which are focused on improving patient health outcomes. Life sells term life and final expense products.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.